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Abstract
Background: Asthma is one of the most common chronic respiratory conditions worldwide. Asthma-related
economic burden has been reported in Latin America, but knowledge about its economic impact to the Colombian
health care system and the influence of disease severity is lacking. This study estimated direct medical costs and health
care resource utilization (HCRU) in patients with asthma according to severity in Colombia.
Methods: This study identified all-age patients who had at least one medical event linked to an asthma
diagnosis (CIE-10: J45-J46) between 2004 and 2014. Patients were selected if they had a continuous enrollment and
uninterrupted insurance coverage between January 1–2015 and December 31–2015 and were categorized into 4
different severity levels using a modified algorithm based on Leidy criteria. Healthcare utilization and costs were
estimated in a 1-year period after the identification period. A Generalized Linear Model (GLM) with gamma distribution
and log link was used to analyze costs adjusting for patient demographics.
Results: A total of 20,410 patients were included: 69.5% had mild intermittent, 18.0% mild persistent, 6.9% moderate
persistent and 5.5% severe persistent asthma; with mean costs (SD) of $67 (134), $482 (1506), $1061 (1983), $2235
(3426) respectively (p < 0.001). The mean total direct cost was estimated at $331 (1278) per patient. Medication and
hospitalization had the higher proportion in total costs (46% and 31% respectively). General physician visits was the
most used service (57.2%) and short-acting β-2 agonists the most used medication (24%).
Conclusions: Health services utilization and direct costs of asthma were highly related to disease severity. Nationwide
health policies aimed at the effective control of asthma are necessary and would play an important role in reducing
the associated economic impact.
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Background
As the most prevalent chronic respiratory disease world-
wide, asthma contributes enormously to the total
economic burden of non-communicable diseases [1–3].
This chronic and difficult-to-treat condition demands
high expenditures in medical care services and impairs
quality of life and productivity of patients [4, 5]. Recent
estimations indicated that asthma caused 1.1% of global
disability-adjusted life years (DALYs). From 1990 to
2015, its global prevalence increased by 12.6%, affecting
358.2 million all-age individuals worldwide [6–8].
Annual asthma-related direct costs are highly variable
among countries. Estimations have been reported from
less than US$150 per person-year in Abu Dhabi, United
Arab Emirates to more than US$3000 per person-year in
the United States (US) [9]. Disease severity is considered
a major factor influencing health care resource utilica-
tion (HCRU) and related costs. Even though severe
asthma is not common, its contribution to total costs is
high [10–13].
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Despite some pharmacological advances and the divulga-
tion of guidelines for diagnosis, treatment and prevention,
asthma is still a global difficult-to-treat condition and the
implementation of strategies for achieving better outcomes
remains heterogeneous, especially in developing countries
[14–18]. In Latin America, as in other developing regions
in the world, several barriers exist to achieve asthma con-
trol [19–21]. Disease mechanisms are poorly understood
and co-existence of infectious and chronic diseases repre-
sents major challenges to health care systems [22–25]. As a
result, high rates of uncontrolled and severe asthma have
been reported and asthma remains neglected as a public
health priority [26–28].
Colombia is a predominantly urban country (76%) of
over 48 million inhabitants where chronic diseases are
emerging as public health concerns [29]. In 1993, the
Colombian Congress sanctioned the Law 100, which
replaced the former National Health System (NHS) and
introduced a healthcare system known as “Sistema Gen-
eral de Seguridad Social en Salud (SGSSS) (The General
System of Social Security in Health)”, an obligatory na-
tional health insurance system based on regulated com-
petition. Formally employed individuals, retirees or
self-employed individuals earning at least the minimum
wage must contribute to SGSSS through a mandatory
payroll deduction (contributive regime) and individuals
from the low-income population (near 23 million) are
affiliated through governmental subsidies (subsidized re-
gime). Currently, almost of 95% of the population is cov-
ered by SGSSS and both have equal access to healthcare
services.
A nationwide study conducted in Colombia estimated
a prevalence rate of 12% (95% CI: 10.5–13.7) for current
asthma symptoms suggesting an increase compared to a
10% rate (95% CI: 9.7–11.1) reported 10 years earlier.
Furthermore, 43% of subjects with reported asthma
symptoms also informed requiring an emergency
department (ED) visit or hospitalization in the past year
[30, 31]. Nevertheless, little is known about the eco-
nomic burden of asthma in Colombia and cost of illness
studies assessing the influence of disease severity in
direct costs and HCRU have not been conducted.
There are no studies in Latin America assessing
asthma-related costs through claim-based approaches
and micro-costing methodologies in spite of their useful-
ness as inputs for economic evaluations. Thus, current
estimations are associated with uncertainty as high
variability in study designs exists. Determining the costs
of asthma will help to identify the main expenditure pre-
dictors, to analyze if current spending is allocated effect-
ively and to suggest how it should be invested in the
future. Assessing the direct medical costs is a valuable
input in the design, monitoring and evaluation of health
policies and strategies for disease management. In
addition, targeting strategies to approach specific groups
of the population with asthma according to cost predic-
tors, may contribute to reduce the resulting economic
burden and therefore to improve efficiency in the re-
source allocation process. In this study, we sought to es-
timate the HCRU and direct medical costs of asthma for
different severity stages from the Colombian health care
system perspective.
Methods
Data source
The primary data source for cost estimation was a claims
database from a subsidized regime insurance company of
national coverage (with almost two million affiliates) that
provides health services to the poorest populations that
are not affiliated to the health system through formal em-
ployment. Person-level information on demographics,
HCRU and total expenditures were available for the study.
Study design
This was a retrospective analysis of a claims database to
estimate the utilization of medical services and
asthma-related medication within an open cohort of
asthmatic patients. We used a stepwise process to
identify and select patients for inclusion as well as for
disease severity assessment. Patients were identified
from January 1, 2004 through December 31, 2014. An
“asthma patient” was defined as any occurrence of an
International Classification of Diseases, Tenth Revision
(ICD-10) code J45 and/or J46 linked to a medical event
such as outpatient visit, ED visit or hospitalization dur-
ing the identification period. Then, to select the most ac-
curate sample among the eligible patients, an individual
must have fulfilled a continuous enrollment and uninter-
rupted health insurance coverage for at least 12 months
during the cost analysis period (from January 1, 2015
through December 31, 2015) (Fig. 1) to be included in
the study. In addition, to ensure quality of information, a
physician of the research staff revised image/laboratory
procedures and prescription data from selected cases to
filter and include only those derived from asthma man-
agement and not with other unrelated co-morbidity.
Disease severity classification
Asthma severity classification was mainly based on Leidy
criteria [32, 33]. This algorithm has been used previously
in other administrative claims studies [34–36] and is
based on the number of β2-agonist inhalers and oral
corticosteroid (OCS) fills used during the year of cost
analysis. The number of exacerbations was also included
in the algorithm of classification for minimizing the like-
lihood of underassessment of severity. An exacerbation
was defined as an ED visit or hospitalization within the
cost analysis period.
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Mild intermittent asthma was defined as one (or less)
SABA fill and zero oral OCS fills per year and zero exac-
erbations. Mild persistent asthma was defined by four to
six SABA fills and zero oral OCS fills per year, or two to
three SABA fills and less than two OCS fills per year, or
one exacerbation. Furthermore, one (or less) SABA fill
and one oral OCS fills per year can also account for mild
persistent asthma. Moderate persistent asthma included
more than six SABA fills and less than two OCS fills per
year, or four to six SABA fills and one to two OCS fills
per year or 2–3 exacerbations. Patients with severe per-
sistent asthma required to have more than six SABA fills
per year, and the number of OCS fills per year, was
greater than or equal to two or 4 or more exacerbations.
Moreover, zero to six SABA fills and three or more
SABA fills per year also constitute severe persistent
asthma [33].
Patient information
Demographic (i.e., age, sex and place of residence) and
socioeconomic characteristics (the category in the infor-
mation system used in Colombia to identify potential
beneficiaries of public spending – SISBEN) [37] of the
final sample were stratified and compared among
asthma severity categories. Associated comorbidities
were identified on the claims database as the additional
occurrence of their respective ICD-10 codes on the sam-
ple of asthmatic subjects.
Direct costs
Costs derived from medical services: hospitalizations,
ED visits, outpatient visits, specialized care and other
ambulatory services (i.e., domiciliary care, laboratory/
image procedures and ambulances) as well as prescrip-
tions of controller or rescue medications (see Additional
file 1) were obtained directly from the billing database of
the health insurance company. The cost per patient was
calculated in each type of health care resource (or medi-
cation category) as the sum of the cost of the respective
events reported during 2015. Mean costs were estimated
among all subjects belonging to each disease category or
among only those who used the medical service or
received the prescription. The total cost per patient in-
cluding all expended medical services and all prescrip-
tions (or both) was also calculated to further estimate
mean total costs. To allow for cost comparability, 2015
purchasing power parity (PPP) exchange rate from
the World Bank International Comparison Program
Database was used to convert costs estimations to
2015 International Dollars (I$). Total expenditures
were divided by the PPP exchange rate ($1203.9
COP) [38]. Purchasing Power Parity adjustment allows
a comparable analysis of economic data from different
countries by expressing expenditures in a common
price index (i.e., based in US) due to potential differ-
ences in purchasing powers between countries despite
conversion using market exchange rates. A PPP
exchange rate is the number of units of a country
currency required to purchase the same amounts of
goods and services in the domestic market as a US
dollar would buy in the US. An International Dollar
is therefore a hypothetical currency that has the same
purchasing power as the US Dollar has in the US for
similar goods and services [39–41].
IDENTIFICATION PERIOD
Jan 01,2004-Dic 31, 2014
COST ANALYSIS PERIOD
Jan 01, 2015-Dic 31, 2015
All-age patients affiliated to 
the insurance company 
(N = 1,600,244)
All-age patients with any 
medical event related to
ICD-10 asthma diagnosis 
code 
(n = 65,751)  (4.1 %)
Eligible patients within 
identification period
(n =23,902)
Final sample for analysis 
(n = 20,410)
Patients excluded:
-Died (n =436)
- Disenrollment 
permanently from the 
insurance plan
(n = 6,000)
-No asthma-related service 
use (n = 35,413)
Patients excluded:
-No diagnosis of asthma
(n = 1,534,493)
Patients excluded 
-No continuous enrollment
(n = 3,418)
-Died in 2015 (n = 74)
Fig. 1 Patient identification and selection process
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Sensitivity analysis
We analyzed the impact of other respiratory co-morbid-
ities and allergic diseases on asthma-related direct costs
by performing a sensitivity analysis. All patients with any
of the selected co-morbidities (i.e., rhinitis, atopic ec-
zema, acute bronchitis, pulmonary emphysema and
COPD) were excluded and total costs compared with
the entire database. Sub-group analyses in age-categories
with more potential of misclassification with other re-
spiratory diseases were also done.
Statistical analysis
Data analysis was performed in Stata 14 software
(StataCorp LP Lakeway, TX, US) and R statistical
software version 3.3.4. Descriptive information about
clinical and sociodemographic data of patients in-
volved in the study is shown in Table 1. Differences
between proportions were analyzed by Pearson
chi-squared test. The Cochran-Armitage test was used
for trend association analysis.
Costs were reported both as their arithmetic mean with
standard deviation (SD) and median with interquartile
range (IQR). The Shapiro-Wilk test was used to test for
normal distribution of the cost data and the Levene test to
evaluate homogeneity of variances. The International
Society of Pharmacoeconomics and Outcomes Research –
ISPOR good research practice guidelines were used for cost
data analysis [42]. As the sample/arithmetic mean cost is
considered to be the most appropriate and informative
measure for health care policy-makers, the Welch analysis
of variance- ANOVA test and the Games-Howell test for
post hoc analyses were used for analyzing mean costs
among disease severity categories despite unequal variances
and a non-normal distribution were found in the cost data
[43–45]. In addition, as recommended by Mihaylova et al.
[46] and highlighted by Gray et al. [47], “simple methods”
(assuming normal distributions for costs) should be
preferred when sample sizes are sufficiently large for the
central limit theorem to exert itself.
To identify factors influencing asthma-related costs in
the study population, expenditures were also analyzed in
a one-part generalized linear model (GLM) with gamma
distribution, log-link function and robust standard er-
rors. GLM models with gamma distribution are consid-
ered to be the most suitable option for cost data analysis
due to the advantage of analyzing both the mean and
variance functions on the original dollar scale and
addressing the frequently right-skewed distribution of
cost data [46–49]. The association of the different
sociodemographic covariates (i.e., place of residency,
co-morbidities, etc.) and disease severity with
asthma-related costs (as dependent variable) was ex-
plored by univariate analysis. Potential confounders (age,
gender and SES) and those predictors with a p-value <
0.1 were included in the multivariate model. Estimated
coefficients were reported as cost ratios (exponentiated
form) which can be interpreted as a ratio of adjusted
costs between the category of interest versus the cat-
egory of reference for binary predictors or as the per-
centage of increase in the mean cost per unit increase in
a continuous covariate [50–52]. A p-value less than 0.05
was considered statistically significant. Predicted ad-
justed costs were also used for comparisons in regard to
clinical and sociodemographic features.
Results
Sample characteristics
The identification and selection process of the study
sample is shown in Fig. 1. A final sample of 20,410
patients was analyzed. Frequencies of disease severity
categories were: 69.5%, 18.0%, 6.9% and 5.5% for mild
intermittent, mild persistent, moderate persistent and se-
vere persistent asthma, respectively. As shown in Table 1,
distribution of socio-demographic features and co-mor-
bidities was significantly different among asthma severity
categories. Living in an urban setting and having a low
socioeconomic status (patients in the first category of
SISBEN index) were predominant characteristics among
all severity stages. With regard to comorbidities, atopic
eczema and COPD cases were concentrated in the
0-4 yr. (45.2%) and > 60 yr. (50.7%) age groups, respect-
ively (see Additional file 2). The estimated prevalence
for atopic eczema and COPD for these age groups was
4.1% and 43.4%, respectively.
Health care resource utilization
General physician visit (57.2%) was the most commonly
used medical service and emergency department (ED)
visit, the least (3.5%). Frequency distribution of
asthma-related services in regard to disease severity is
shown in Table 2. The overall frequency of HCRU
increased significantly with disease severity (p for a
trend = 0.026), but it was only evident among persistent
asthma categories. When analyzed individually, the use
of most services also increased significantly with
disease severity in contrast to ED visits that showed a
negative trend.
Unadjusted direct costs according to disease severity
Mean costs of asthma-related medical services and med-
ications increased in regard to disease severity (Table 3)
except for ED visits that showed no differences (p =
0.187). The estimated mean annual (SD) direct cost per
patient was I$331 (1278). Costs for mild intermittent,
mild persistent, moderate and severe persistent asthma
were I$67 (134), I$482 (1506), I$1061 (SD 1983) and
I$2235 (SD 3426) respectively (p < 0.001). Among
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medical services and medications, hospitalizations and
SABA treatment had the highest mean costs, respec-
tively. Mean and median direct costs among only those
who used asthma-related resources are presented in
Additional files 3 and 4, respectively. Significant diffe-
rences were found among costs distributed by age
groups (p < 0.001) and the highest costs were observed
for patients older than 60 yr. (I$533) (1942), those be-
tween 45 and 59 yr. (I$391) (1160) and children ≤4 years
old (I$352) (1233).
With respect to the distribution of costs according to
the type of service and severity (Fig. 2), medication ex-
penditures accounted for almost half of the total direct
costs (46.1%) with the highest proportions in moderate
and severe persistent groups (53% and 61.3%,
respectively). Hospitalizations expenditures accounted
for 31.8% of total costs and were more concentrated
among patients in the mild persistent category (49.6%)
compared to moderate and severe persistent (34.7% and
29.6%, respectively). The overall proportion of costs re-
lated to general physician visits was 11.4% and was
higher among mild intermittent patients (44.7%), but de-
creased across the other three categories. Total annual
direct costs were estimated to be I$6.7 million.
Direct cost predictors
Having a comorbid condition (i.e., COPD, rhinitis, acute
bronchitis), more severe asthma, belonging to highest-so-
cioeconomic status (SISBEN 2–3 versus 1 as reference)
Table 1 Patient characteristics at baseline in relation to asthma severity - 2015
All patients
n = 20,410
Mild intermittent
n = 14,191
Mild Persistent
n = 3680
Moderate Persistent
n = 1408
Severe persistent
n = 1131
p-value a
Characteristic
Age in years, mean (SD) 23.9 (24.6) 23.4 (23.9) 23.7 (25.0) 27.4 (27.8) 26.3 (27.2) < 0.001
Age, n (%)
0-4y 7377 (36.1) 4913 (34.6) 1426 (38.7) 543 (38.5) 495 (43.7) < 0.001
5-9y 3060 (14.9) 2280 (16.0) 482 (13.1) 178 (12.6) 120 (10.6)
10-14y 1619 (7.9) 1174 (8.2) 300 (8.1) 93 (6.6) 52 (4.6)
15-19y 804 (3.9) 614 (4.3) 135 (3.6) 32 (2.2) 23 (2.0)
20-44y 2964 (14.5) 2196 (15.4) 523 (14.2) 141 (10.0) 104 (9.2)
45-59y 1989 (9.7) 1344 (9.4) 340 (9.2) 153 (10.8) 152 (13.4)
>60y 2597 (12.7) 1670 (11.7) 474 (12.8) 268 (19.0) 185 (16.3)
Gender
Female, n (%) b 10,847 (53.6) 7599 (54.1) 1937 (52.9) 761 (54.2) 550 (48.7) 0.005
Place of residency
Urban 16,357 (80.1) 11,147 (78.5) 3101 (84.2) 1164 (82.6) 945 (83.5) < 0.001
Rural 4053 (19.8) 3, 044 (21.4) 579 (15.7) 244 (17.3) 186 (16.4)
SISBEN level c
1 17,641 (86.4) 12,277 (86.5) 3195 (86.8) 1192 (84.6) 977 (86.3) 0.028
2 1943 (9.5) 1352 (9.5) 317 (8.6) 167 (11.8) 107 (9.4)
3 99 (0.5) 72 (0,5) 14 (0.3) 7 (0.5) 6 (0.5)
Other 727 (3.5) 490 (3.4) 154 (4.1) 42 (2.9) 41 (3.6)
Comorbidities
Rhinitis 1209 (5.9) 709 (5.0) 248 (6.7) 132 (9.4) 120 (10.6) < 0.001
Acute Bronchitis 350 (1.7) 187 (1.3) 74 (2.0) 52 (3.7) 37 (3.2) < 0.001
COPD 2223 (10.9) 1081 (7.6) 475 (12.9) 340 (24.2) 327 (28.9) < 0.001
Atopic Eczema 667 (3.2) 424 (2.9) 141 (3.8) 70 (4.9) 50 (4.4) < 0.001
Pulmonary Emphysema 71 (0.3) 29 (0.2) 17 (0.4) 14 (1) 11 (1.9) < 0.001
a Pearson Chi-square test for proportions and Welch ANOVA test for continuous variables
b There were 179 patients of which information about sex was not available
c The System for Selecting Beneficiaries of Social Spending (SISBEN) is a proxy-means instrument for targeting social spending based in an assessment of the
socio-economic vulnerability of families according to their living conditions. The first level involves the most deprived populations and the third the relatively
less deprived
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and living in an urban setting were significant predictive
factors for greater direct costs. No associations of costs
with sex and age were found. Neither atopic eczema nor
emphysema as co-morbidities were significantly related to
direct costs (p = 0.066 and p = 0.064, respectively). The
cost ratios (exponentiated form of estimated coefficients)
of covariates are shown in Table 4. Adjusted mean (SD)
cost of any patient with asthma was I$336 (615). Direct
costs were higher in patients with severe persistent asthma
compared to the other categories (p < 0.001). Adjusted
mean costs stratified by different characteristics (age,
gender, asthma severity, etc.) are shown in Table S5 (see
Additional file 5).
Sensitivity analysis
Three different sensitivity analyses were conducted.
First, exclusion of asthmatic patients with any of the five
selected comorbidities decreased total costs by 39.7%
(from I$6.7 million to I$4 million). Asthmatic patients
with COPD added I$1.9 million (or 29%) to direct costs
of the total sample of patients with asthma. Analysis in
the sub-groups indicated that the mean annual cost per
patient decreased from I$391 to I$236 (39.6%) and
I$533 to I$308 (42.2%) in the age groups of 45-59 yr.
and > 60 yr., respectively. In addition, asthmatic pa-
tients with acute bronchitis added I$361,000 to total
costs estimations and the exclusion of children with
this co-morbidity decreased the mean cost by less
than 2% (from I$352 to I$347) among those in the
0-4 yr. of age group.
Discussion
This is the first claim-based study in Colombia that esti-
mated the economic burden of asthma in terms of direct
costs and its differences between disease severity catego-
ries. As expected, most severe cases of asthma incurred
greater direct costs. Mean costs had a positive trend in
relation with disease severity. Medication and
Table 2 Health care services and medication utilization related to severity
Total
n = 20,410
Mild
intermittent
n = 14,191
Mild
Persistent
n = 3680
Moderate Persistent
n = 1408
Severe persistent
n = 1131
p-valuea
Medical services (n, %)b
ED visits* 721 (3.5) – 462 (12.5) 163 (11.5) 96 (8.5) < 0.001
Mean (SD)c 1.1 (0.5) – 1 (0) 1.3 (0.5) 1.4 (1.1)
Hospitalizations* 1137 (5.5) – 495 (13.4) 278 (19.7) 364 (32.1) < 0.001
Mean (SD)c 1.6 (1.6) – 1 (0) 1.5 (0.6) 2.5 (2.6)
Specialized physician visits 5764 (28.2) 3539 (24.9) 1057 (28.7) 578 (41.0) 590 (52.1) < 0.001
General physician visits 11,685 (57.2) 8445 (59.5) 1761 (47.8) 755 (53.6) 724 (64.1) < 0.001
Other ambulatory services 1653 (8.1) 1009 (7.1) 297 (8.0) 160 (11.3) 187 (16.5) < 0.001
Total frequency of any medical service 17,059 (83.5) 11,933 (84.1) 2923 (79.4) 1167 (82.8) 1036 (91.6) 0.026
Asthma medication prescriptions (n, %)b
Controller medications
ICS 4841 (23.7) 1777 (12.5) 1410 (38.3) 821 (58.3) 833 (73.6) < 0.001
ICS + LABA 487 (2.4) 32 (0.2) 88 (2.4) 171 (12.1) 196 (17.3) < 0.001
LABA 188 (0.9) 18 (0.1) 65 (1.7) 38 (2.7) 67 (5.9) < 0.001
LM 660 (3.2) 0 (0) 221 (6.0) 154 (10.9) 285 (25.2) < 0.001
Theophylline 240 (1.1) 36 (0.2) 62 (1.6) 63 (4.4) 79 (6.9) < 0.001
Rescue Medications
Oral corticosteroids 4594 (22.5) 399 (2.8) 2236 (60.7) 998 (70.8) 961 (84.9) < 0.001
SABA 4911 (24.0) 1242 (8.7) 1798 (48.8) 946 (67.2) 925 (81.8) < 0.001
Total frequency of any medication 9509 (46.6) 3880 (27.3) 3183 (86.5) 1336 (94.9) 1110 (98.1) < 0.001
*For ED visits and hospitalizations trend analysis was conducted for mild to severe persistent categories
aCochran-Armitage test. P for trend is reported
bThe number of patients using each medical service is reported. Relative frequencies were calculated using the total number of subjects (N) for each column as
denominator. Patients may have used more than one service in the cost analysis period
cMean number of times that a patient required to use this medical service during the cost analysis period
ED emergency department; ICS inhaled corticosteroids; ICS + LABA inhaled corticosteroids-long acting B2 agonist combination; LABA long acting B2 agonist; LM
leukotriene modifiers; SABA short acting B2 agonist
Flórez-Tanus et al. World Allergy Organization Journal  (2018) 11:26 Page 6 of 11
hospitalizations accounted for approximately 78% of the
total costs in the general cohort. In spite that patients
with severe persistent asthma accounted for about 5% of
the total sample, these cases contributed to more than a
third of total costs (37%). Unadjusted as well as adjusted
mean costs showed a positive trend with disease severity.
Also, patients between 0 to 4 yrs. and > 60 yr. of age
were significantly more likely to have had history of
comorbidities and its effect in costs was considerable.
The influence of asthma severity and control levels in
direct costs have been previously documented in some
countries of Latin America [28, 53], but no information
about Colombia has been published yet. The availability
of large scale statistics of HCRU is mainly restricted to
high-income countries [12, 54] and data are lacking for
most low-and middle-income countries [2]. Gold et al.
[55] used the Latin America Asthma Insights and Man-
agement Survey (LA AIM) to assess different levels of
asthma control based on Global Initiative for Asthma
(GINA) guidelines in five countries, and found that a
poor control was a significant factor influencing health
care resources use and greater medical costs, ranging
from $70 for a well-controlled patient in Brazil, for an
$5400 uncontrolled patient in Argentina (2013 US
dollars). However, Colombia was not included in this
study and therefore it is difficult to make a comparison
of our results with previous estimations.
In addition, the Asthma Insights and Reality in Latin
America (AIRLA) survey, conducted in 11 countries of
the region, including Colombia, demonstrated the con-
siderable lag in asthma care and control existing in
these countries [28]. Based on the AIRLA survey,
Neffen et al. [53], found that approximately 73.2% of
annual costs of asthma-related health care for 10 countries
in Latin America were due to unscheduled health care and
overall related expenditure was higher among adults and
children with severe persistent asthma symptoms (2010
US$558 and $769, respectively). Nevertheless, researchers
were unable to include medication costs in this study; thus,
estimations may underestimate the total economic impact
in terms of direct costs. Even though these studies have
contributed to the knowledge of asthma costs in the region,
there is a potential limitation linked to their design (sur-
vey-based); frequencies may be underestimated, mainly be-
cause outcomes are reported by patients (recall bias) [56].
In Colombia, Hinestrosa et al. [57] conducted a retro-
spective analysis of clinical data (n = 2007) obtained
from a hospital in a municipality of Colombia and found
Table 3 Unadjusted direct mean annual asthma-related mean costs by category of service and severity
Service a Total
n = 20,410
Mild intermittent
n = 14,191
Mild Persistent
n = 3680
Moderate Persistent
n = 1408
Severe persistent
n = 1131
p-value b
Medical services c
ED visits $6 (39.3) – $21 (57) $26 (78) $20 (87) 0.187
Hospitalizations $105 (946) – $239 (1492) $368 (1838) $662 (2027) 0.000
Specialized physician visits $20 (47) $15 (35) $23 (52) $38 (66) $58 (91) 0.000
General physician visits $37 (61) $30 (39) $41 (59) $54 (77) $100 (158) 0.000
Other ambulatory services $7 (68) $5 (61) $9 (85) $10 (49) $22 (99) 0.000
Any medical service d $178 (958) $51 (76) $335 (1489) $498 (1840) $865 (2050) 0.000
Asthma medication prescriptions c
Controller medications
ICS $20 (124) $5 (52) $28 (117) $84 (269) $101 (306) 0.000
ICS + LABA $24 (211) $0.7 (19) $12 (115) $147 (513) $208 (606) 0.000
LABA $0.5 (16) $0 (2) $0.7 (14) $0.8 (11) $5 (62) 0.000
LM $12 (89) $0 (0) $10 (61) $37 (143) $137 (296) 0.000
Rescue Medications
Oral corticosteroids $14 (74) $0.3 (7) $15 (36) $48 (100) $138 (249) 0.000
SABA $25 (127) $3 (27) $38 (114) $98 (231) $166 (375) 0.000
Any medication e $152 (780) $16 (108) $147 (320) $563 (895) $1370 (2755) 0.000
Total mean costs f $331 (1278) $67 (134) $482 (1506) $1061 (1983) $2235 (3426) 0.000
a Mean values and their (SD) are reported and were calculated using the total number of subjects in each column as denominator
b Welch analysis of variance-ANOVA test
c One patient may contribute to the costs of different medical services or prescriptions
d, e, f Mean values represent the sum of costs derived from all medical services d, medications e (or both f ) presented during the cost-analysis period and
divided by the total number of subjects in each disease category.
ED emergency department; ICS inhaled corticosteroids; ICS+LABA inhaled corticosteroids-long acting B2 agonist combination; LABA long acting B2 agonist; LM
leukotriene modifiers; SABA short acting B2 agonist
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that between 2007 and 2009, medication was the main
source of asthma-related direct cost (74%) derived
mainly by inhaled corticosteroids. Similar results have
been observed in previous studies in different countries,
medication and hospitalization being the largest contrib-
utors. In 1985, hospital inpatient costs were estimated as
the largest component cost of direct medical expendi-
tures in the United States (44.6%) but, in 1994, medica-
tions had the higher proportions (40.1%) [58, 59]. Our
study suggests a similar cost distribution with
medications as the most important cost-deriver and
SABA treatment accounting for the highest proportion
of total cost among mild and moderate persistent
asthma patients.
Living in an urban setting and higher SES were pre-
dictive factors for greater asthma expenditures in our
study. Although there are many possible explanations
(differences in the availability/proximity of health care
services, level of education, environmental factors and
even reverse causality) we were unable to identify causal
Table 4 Generalized Linear Model (GLM) analysis of total direct costs (N = 19,509)
Parameter Coefficient Robust S.E. p-value 95% CI
Intercept 47.01 5.28 0.000 37.72 58.59
Age (continuous) 1.00 0.00 0.640 0.99 1.00
Female gender (ref: male gender) 0.97 0.02 0.372 0.92 1.03
Socioeconomic status (ref: Levels 2–3 in SISBEN index)
Level 1 0.88 0.04 0.028 0.79 0.98
Rhinitis 1.76 0.12 0.000 1.53 2.02
Acute Bronchitis 1.34 0.15 0.009 1.07 1.67
Atopic eczema 1.12 0.06 0.066 0.99 1.26
COPD 1.65 0.10 0.000 1.46 1.87
Emphysema 1.29 0.18 0.064 0.98 1.71
Severity Index (ref: mild intermittent)
Mild persistent asthma 6.63 0.35 0.000 5.97 7.36
Moderate Persistent asthma 13.59 0.77 0.000 12.15 15.20
Severe persistent 28.84 1.44 0.000 26.14 31.82
Urban residency (ref: rural residency) 1.15 0.43 0.000 1.07 1.24
S.E. standard error
Fig. 2 Distribution of total direct costs according to asthma severity. Cumulative percentage of total cost per category of severity among the
different cost components
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relationships by means of this retrospective and cross--
sectional study design [60]. With regard to comorbid-
ities, the asthma and COPD overlap considerably
increased costs compared to patients who had only
an asthma diagnosis, indicating that COPD is also an
important source of economic burden and this group
of patients should be a target for policies aimed at re-
ducing the burden associated with chronic respiratory
diseases [61, 62].
The high prevalence of SABA treatment use in our
findings may indicate poor adherence to controller med-
ications or potential lack of knowledge about the efficacy
of novel therapies in asthma treatment as well as estab-
lished guidelines for asthma management by physicians
in a clinical setting [63, 64]. The use frequency of SABA
was similar to that of IC, but considerably high com-
pared to IC + LABA combination. Together with a high
rate of rescue medication, it was observed that IC pre-
scriptions – the gold standard controller medication for
persistent asthma [15] – were lower than expected. This
improper management could also be explained by a low
frequency of specialized physician visits even in those
categorized as severe asthma (52%). In this regard, this
scenario of poor asthma control and insufficient medical
attention associated with elevated costs due to exacerba-
tions and medication could imply the need for changes
in Colombian policies for asthma treatment, including
the creation of care management programs as observed
in other Latin American countries [65].
This study has limitations in its methodology. Due to its
focus on the third payer perspective, this work has restric-
tions to estimate epidemiologically important variables
that may reflect asthma control. Frequency of exacerba-
tions in asthmatic patients may be underestimated since
many cases may have been treated at home. This could
also explain why frequency of exacerbations are lower
than those reported in the literature [30]. A negative trend
in ED visits as disease severity increased may be explained
by the positive direction in hospitalization frequencies.
Our sample was not representative of the total population
with asthma in Colombia; since our data was provided by
an insurance company that offers health care services to
less affluent inhabitants, estimations may be biased to
reflect expenditures of this part of the population. Since
indirect and direct non-medical asthma-related costs were
not included, the total economic burden of asthma in
Colombia is underestimated. Due to the nature of admin-
istrative databases, it is not possible in this type of study
to assess disease control, nor to classify asthma severity
according to the clinical criteria defined by internationally
well-accepted guidelines or methods (i.e. GINA/ NAEPP
guidelines or ERS/ATS) since claims information does not
include direct clinical data inputs which usually are de-
rived from medical charts, such as measures of daily
symptoms, lung function, forced expiratory volume or
peak expiratory flow [15, 18, 33]. However, the use of ad-
ministrative claims data provides valuable information to
estimate the magnitude in which asthma imposes an eco-
nomic burden and it is, therefore, an important input for
conducting economic evaluations [66, 67].
Although there is not a best-practice established
algorithm for assessing disease severity in patients with
asthma using administrative data, we considered that from
those available in the literature, Leidy criteria is a reliable
method for disease classification and the most suitable for
analyzing information obtained from Colombian health
system records. However, we aimed to optimize this classi-
fication adding exacerbation data, which are highly repre-
sentative of disease severity. The implementation of an
algorithm based in Leidy criteria in the Colombian context
was possible due to the improvement of health care infor-
mation systems and the availability of codified and docu-
mented data of health care utilization by patients.
Limitations of prescription data for disease severity defin-
ition have been discussed by others [33]; for example, it
does not ensure medication use by patients. In addition,
prescriptions may be subjectively determined by the phys-
ician opinion and not accurately reflect asthma severity.
In the absence of empirical and clinical studies, this
methodology can be further applied to other disease
groups in the context of the developing world as a useful
mechanism for generating evidence to health policy cre-
ation and evaluation. However, considerable improve-
ments are required as there has been relatively little
progress in data analysis and application despite a rapid
rise of data production in this particular setting [68].
Conclusions
Asthma severity is an important factor for increasing
disease-related HCRU and direct costs. Our results dem-
onstrate the considerable economic burden of asthma to
health systems in the context of the developing world.
Reinforcement of asthma control programs, with a focus
on disease severity and the integral management of
co-morbidities, may optimize the efficacy of intervention
strategies and reduce costs to the health system.
Additional files
Additional file 1: Table S1. Asthma medication (DOCX 18 kb)
Additional file 2: Table S2. Distribution of comorbidities according to
age (DOCX 13 kb)
Additional file 3: Table S3. Unadjusted direct mean annual asthma-
related costs among health care resource users (DOCX 20 kb)
Additional file 4: Table S4. Unadjusted direct median annual asthma-
related costs among health care resource users (DOCX 20 kb)
Additional file 5: Table S5. Adjusted direct mean annual asthma-
related costs by patient characteristics (DOCX 15 kb)
Flórez-Tanus et al. World Allergy Organization Journal  (2018) 11:26 Page 9 of 11
Abbreviations
COPD: Chronic obstructive pulmonary disease; ED: Emergency department
visit; GLM: Generalized Linear Model; HCRU: Health Care Resource Utilization;
ICS + LABA: Inhaled corticosteroids-long acting B2 agonist combination;
ICS: Inhaled corticosteroids; LABA: Long acting B2 agonist; OCS: Oral
corticosteroid; PPA: Purchasing Power Parities; SABA: Short-acting β2-agonist;
SISBEN: System for Selecting Beneficiaries of Social Spending
Acknowledgements
We are grateful with COOSALUD for providing the database of medical
claims for this study. Special thanks to Alexandra O’Rourke for her assistance
in the language revision of the manuscript.
Funding
This research was supported by the Colombian government (Departamento
Administrativo de Ciencia y Tecnología e Innovación, Colciencias) through
the grant #406–2011 and the scholarship Jovenes Investigadores, University
of Cartagena and The Foundation for the Development of Medical and
Biological Sciences (Fundemeb).
Availability of data and material
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
Data analysis (DP and AF), data interpretation (DP, AF, JZ and NA), writing
(DP, AF, JZ and LC), study design (NA) or critical revision (LC). All authors
read approved the final manuscript.
Ethical approval
This study was approved by the Ethical Committee of the University of
Cartagena (Minute 36, October 11th 2011).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Health Economics Research Group, University of Cartagena, Campus Piedra
de Bolívar, Cartagena, Colombia. 2Center for Research and Innovation in
Health, Coosalud, Street 11 – 2 Floor 8, Bocagrande, Cartagena, Colombia.
3Institute for Immunological Research, University of Cartagena, Campus de
Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia. 4Foundation
for the Development of Medical and Biological Sciences (Fundemeb), Cra 5
#7-77, Cartagena, Colombia. 5Hospital Management and Health Policy
Research Group, Universidad de la Costa, Barranquilla, Colombia. 6ALZAK
Foundation, Calle 70 #6-99, Cartagena, Colombia.
Received: 28 February 2018 Accepted: 10 September 2018
References
1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive
summary of the GINA dissemination committee report. Allergy. 2004;59:
469–78. https://doi.org/10.1111/j.1398-9995.2004.00526.x.
2. The Global Asthma Report 2014. Auckland, New Zealand: 2014.
3. Hay S, Abajobir AA, Abate KH, et al. Global, regional, and national disability-
adjusted life-years (DALYs) for 333 diseases and injuries and healthy life
expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic
analysis for the global burden of disease study 2016. Lancet. 2017;390:1260–
344. https://doi.org/10.1016/S0140-6736(17)32130-X.
4. Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national
deaths, prevalence, disability-adjusted life years, and years lived with
disability for chronic obstructive pulmonary disease and asthma, 1990–2015:
a systematic analysis for the global burden of disease study 2015. Lancet
Respir Med. 2017;5:691–706. https://doi.org/10.1016/S2213-2600(17)30293-X.
5. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults:
findings from the cross-sectional world health survey. BMC Public Health.
2012;12:204. https://doi.org/10.1186/1471-2458-12-204.
6. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a
systematic review. BMC Pulm Med. 2009;9:24. https://doi.org/10.1186/1471-
2466-9-24.
7. Gergen PJ. Understanding the economic burden of asthma. J Allergy Clin
Immunol. 2001;107:445–8. https://doi.org/10.1067/mai.2001.114992.
8. Bousquet J, Bousquet PJ, Godard P, et al. The public health implications of
asthma. Bull World Health Organ. 2005;83:548–54 doi:S0042-
96862005000700016 [pii].
9. Ehteshami-Afshar S, Fitzgerald JM, Doyle-Waters MM, et al. The global
economic burden of asthma and chronic obstructive pulmonary disease. Int
J Tuberc Lung Dis. 2016;20:11–23. https://doi.org/10.5588/ijtld.15.0472.
10. Dilokthornsakul P, Lee TA, Dhippayom T, et al. Comparison of health care
utilization and costs for patients with asthma by severity and health
Insurance in Thailand. Value Heal Reg Issues. 2016;9:105–11. https://doi.org/
10.1016/j.vhri.2016.03.001.
11. Lee YJ, Kwon S-H, Hong S-H, et al. Health care utilization and direct costs in
mild, moderate, and severe adult asthma: a descriptive study using the
2014 south Korean health insurance database. Clin Ther. 2017;39:1–10.
https://doi.org/10.1016/j.clinthera.2017.01.025.
12. Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among
patients with severe asthma in a managed care setting. J Manag Care Spec
Pharm. 2016;22:848–61. https://doi.org/10.18553/jmcp.2016.22.7.848.
13. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource
utilisation. Eur Respir J. 2004;23:723–9. https://doi.org/10.1183/09031936.04.
00004904.
14. Bush A, Kleinert S, Pavord ID. The asthmas in 2015 and beyond: a lancet
commission. Lancet. 2015;385:1273–5. https://doi.org/10.1016/S0140-
6736(15)60654-7.
15. Global Initiative for Asthma. Global Strategy For Asthma Management and
Prevention. 2017.
16. Lalloo UG, Walters RD, Adachi M, et al. Asthma programmes in diverse
regions of the world: challenges, successes and lessons learnt. Int J Tuberc
Lung Dis. 2011;15:1574–86. https://doi.org/10.5588/ijtld.11.0289.
17. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/
European Respiratory Society statement: asthma control and exacerbations -
standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir
Crit Care Med. 2009;180:59–99. https://doi.org/10.1164/rccm.200801-060ST.
18. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on
definition, evaluation and treatment of severe asthma task force report ers/
ats guidelines on severe asthma Executive Summary. Eur Respir J. 2014;43:
343–73. https://doi.org/10.1183/09031936.00202013.
19. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in
children and adults: the global asthma insights and reality surveys. J Allergy
Clin Immunol. 2004;114:40–7. https://doi.org/10.1016/j.jaci.2004.04.042.
20. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in
1999 : the Asthma Insights and Reality in Europe ( AIRE ) study. Eur Respir J.
2000:802–7.
21. Gold LS, Thompson P, Salvi S, et al. Level of asthma control and health care
utilization in Asia-Pacific countries. Respir Med. 2014;108:271–7. https://doi.
org/10.1016/j.rmed.2013.12.004.
22. Beran D, Zar HJ, Perrin C, et al. Burden of asthma and chronic obstructive
pulmonary disease and access to essential medicines in low-income and
middle-income countries. Lancet Respir Med. 2015;3:159–70. https://doi.org/
10.1016/S2213-2600(15)00004-1.
23. Caraballo L, Zakzuk J, Lee BW, et al. Particularities of allergy in the
tropics. World Allergy Organ J. 2016;9:20. https://doi.org/10.1186/s40413-
016-0110-7.
24. Mallol J. Asthma in Latin America: where the asthma causative/protective
hypotheses fail. Allergol Immunopathol (Madr). 2008;36:150–3. https://doi.
org/10.1157/13124721.
25. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Asthma care in
resource-poor settings. World Allergy Organ J. 2011;4:68–72. https://doi.org/
10.1097/WOX.0b013e318213598d.
26. Lopez AD, Williams TN, Levin A, et al. Remembering the forgotten non-
communicable diseases. BMC Med. 2014;12:200. https://doi.org/10.1186/
s12916-014-0200-8.
Flórez-Tanus et al. World Allergy Organization Journal  (2018) 11:26 Page 10 of 11
27. Maspero JF, Jardim JR, Aranda A, et al. Insights, attitudes, and perceptions
about asthma and its treatment: findings from a multinational survey of
patients from Latin America. World Allergy Organ J. 2013;6:1–7. https://doi.
org/10.1186/1939-4551-6-19.
28. Neffen H, Fritscher C, Schacht FC, et al. Asthma control in Latin America: the
asthma insights and reality in Latin America (AIRLA) survey. Rev Panam
Salud Publica/Pan Am J Public Heal. 2005;17:191–7.
29. WHO and UN partners. Colombia: WHO statistical profile. Ctry. Stat. Glob.
Heal. Estim. 2015.http://www.who.int/gho/countries/col.pdf?ua=1 (accessed
12 Dec 2017).
30. Dennis RJ, Caraballo L, García E, et al. Prevalence of asthma and other
allergic conditions in Colombia 2009–2010: a cross-sectional study. BMC
Pulm Med. 2012;12:17. https://doi.org/10.1186/1471-2466-12-17.
31. Dennis R, Caraballo L, García E, et al. Asthma and other allergic conditions
in Colombia: a study in 6 cities. Ann Allergy Asthma Immunol. 2004;93:568–
74. https://doi.org/10.1016/S1081-1206(10)61265-3.
32. Leidy N, Paramore L, Watrous M, et al. Development of an algorithm for
estimating asthma severity from an administrative cost database. Value
Heal. 1999;2:394–5. https://doi.org/10.1016/S1098-3015(10)75867-8.
33. Jacob C, Haas JS, Bechtel B, et al. Assessing asthma severity based on claims
data: a systematic review. Eur J Health Econ. 2017;18:227–41. https://doi.org/
10.1007/s10198-016-0769-2.
34. Ivanova JI, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations
on health care costs among asthmatic patients with moderate and severe
persistent asthma. J Allergy Clin Immunol. 2012;129:1229–35. https://doi.org/
10.1016/j.jaci.2012.01.039.
35. Wells KE, Peterson EL, Ahmedani BK, et al. The relationship between
combination inhaled corticosteroid and long-acting β-agonist use and
severe asthma exacerbations in a diverse population. J Allergy Clin
Immunol. 2012;129:1274–9. https://doi.org/10.1016/j.jaci.2011.12.974.
36. Allen-ramey FC, Bukstein D, Luskin A, et al. Administrative claims analysis of
asthma-related health care utilization for patients who received inhaled
corticosteroids with either Montelukast or Salmeterol as combination
therapy. J Manag Care Pharm. 2006;12:310–21.
37. Castañeda T. Targeting social spending to the poor with proxy–means
testing: Colombia’s SISBEN system. Washington DC; 2005.
38. The World Bank. Purchasing power parity conversion factor. Int Comp Progr
database. 2015; https://dataworldbankorg/indicator/PANUSPPP (accessed 12
Dec 2017.
39. World Health Organization. Choosing Interventions that are Cost Effective
(WHO-CHOICE)-Costs and Prices. http://www.who.int/choice/costs/ppp/en/
40. Drummond M, Barbieri M, Cook J, et al. Transferability of economic
evaluations across jurisdictions: ISPOR good research practices task force
report. Value Heal. 2009;12:409–18. https://doi.org/10.1111/j.1524-4733.
2008.00489.x.
41. Banke-Thomas A, Wilson-Jones M, Madaj B, et al. Economic evaluation of
emergency obstetric care training: a systematic review. BMC Pregnancy
Childbirth. 2017;17:403. https://doi.org/10.1186/s12884-017-1586-z.
42. Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside
clinical trials II—an ISPOR good research practices task force report. Value
Heal. 2015;18:161–72. https://doi.org/10.1016/j.jval.2015.02.001.
43. Barber JA, Thompson SG, Drummond M, et al. Analysis and interpretation of
cost data in randomised controlled trials: review of published studies. BMJ.
1998;317:1195–200. https://doi.org/10.1136/bmj.317.7167.1195.
44. Briggs A, Gray A. The distribution of health care costs and their statistical
analysis for economic evaluation. J Health Serv Res Policy. 1998;3:233–45.
45. Thompson SG, J a B. How should cost data in pragmatic randomised
trials be analysed? BMJ. 2000;320:1197–200. https://doi.org/10.1136/bmj.
320.7243.1197.
46. Mihaylova B, Briggs A, O’Hagan A, et al. Review of statistical methods for
analysing healthcare resources and costs. Health Econ. 2011;20:897–916.
https://doi.org/10.1002/hec.1653.
47. Gray A, Clarke PM, Wolstenholme J, et al. Applied methods for cost-
effectiveness analysis in health care. In: Oxford University press; 2010.
48. Dodd S, Bassi A, Bodger K, et al. A comparison of multivariable regression
models to analyse cost data. J Eval Clin Pract. 2006;12:76–86. https://doi.org/
10.1111/j.1365-2753.2006.00610.x.
49. Manning WG, Mullahy J. Estimating log models: to transform or not to
transform? J Health Econ. 2001;20:461–94. https://doi.org/10.1016/S0167-
6296(01)00086-8.
50. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized
linear models. J Health Econ. 1999;18:153–71. https://doi.org/10.1016/S0167-
6296(98)00032-0.
51. Barber J, Thompson S. Multiple regression of cost data: use of generalised
linear models. J Health Serv Res Policy. 2004;9:197–204. https://doi.org/10.
1258/1355819042250249.
52. Brilleman SL, Gravelle H, Hollinghurst S, et al. Keep it simple? Predicting
primary health care costs with clinical morbidity measures. J Health Econ.
2014;35:109–22.c.
53. Neffen H, Gonzalez SN, Fritscher CC, et al. The burden of unscheduled
health care for asthma in Latin America. J Investig Allergol Clin Immunol.
2010;20:596–601.
54. Janson C, Lisspers K, Ställberg B, Johansson G, Telg G, Thuresson M, Nordahl
Christensen H, Larsson K. Health care resource utilization and cost for
asthma patients regularly treated with oral corticosteroids - a Swedish
observational cohort study (PACEHR). Respir Res. 2018;19(1):168. https://doi.
org/10.1186/s12931-018-0855-3. PubMed PMID: 30176850; PubMed Central
PMCID: PMC6122138.
55. Gold LS, Montealegre F, Allen-Ramey FC, et al. Asthma control and cost in
Latin America. Value Heal Reg Issues. 2014;5:25–8. https://doi.org/10.1016/j.
vhri.2014.06.007.
56. Short ME, Goetzel RZ, Pei X, et al. How accurate are self-reports? Analysis of
self-reported health care utilization and absence when compared with
administrative data. J Occup Environ Med. 2009;51:786–96. https://doi.org/
10.1097/JOM.0b013e3181a86671.
57. Hinestrosa Hurtado F. Cost of illness of asthma in a hospital of the
Colombian region of Caldas 2007–2009. 2010.http://www.bdigital.unal.edu.
co/2996/1/192251.2010.pdf
58. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in
the United States. N Engl J Med. 1992;326:862–6. https://doi.org/10.1056/
NEJM199203263261304.
59. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in
the United States, 1985-1994. J Allergy Clin Immunol. 2000;106:493–9.
https://doi.org/10.1067/mai.2000.109426.
60. Rona RJ. Asthma and poverty. Thorax. 2000;55:239–44. https://doi.org/10.
1136/thorax.55.3.239.
61. Bujarski S, Parulekar AD, Sharafkhaneh A, et al. The asthma COPD overlap
syndrome (ACOS). Curr Allergy Asthma Rep. 2015;15. https://doi.org/10.
1007/s11882-014-0509-6.
62. Blanchette CM, Gutierrez B, Ory C, et al. Economic burden in direct costs of
concomitant chronic obstructive pulmonary disease and asthma in a
Medicare advantage population. J Manag Care Pharm. 2008;14:176–85.
https://doi.org/10.18553/jmcp.2008.14.2.176.
63. Silveira CD, Araújo FDB, Ferreira Pereira LF, et al. Evaluation of the treatment
provided to patients with asthma by the Brazilian unified care system. J Bras
Pneumol. 2009;35:628–34. https://doi.org/10.1093/annonc/mdp346.
64. Aït-Khaled N. Enarson D a., Bencharif N, et al. implementation of asthma
guidelines in health centres of several developing countries. Int J Tuberc
Lung Dis. 2006;10:104–9.
65. Cruz AA, Souza-Machado A, Franco R, et al. The impact of a program for
control of asthma in a low-income setting. World Allergy Organ J. 2010;3:
167–74. https://doi.org/10.1097/WOX.0b013e3181dc3383.
66. Birnbaum HG, Ivanova JI, Yu AP, et al. Asthma severity categorization using
a claims-based algorithm or pulmonary function testing. J Asthma. 2009;46:
67–72. https://doi.org/10.1080/02770900802503099.
67. Thomas M, Cleland J, Price D. Database studies in asthma
pharmacoeconomics: uses, limitations and quality markers. Expert Opin
Pharmacother. 2003;4:351–8. https://doi.org/10.1517/14656566.4.3.351.
68. Wyber R, Vaillancourt S, Perry W, et al. Big data in global health: improving
health in low- and middle-income countries. Bull World Health Organ. 2015;
93:203–8. https://doi.org/10.2471/BLT.14.139022.
Flórez-Tanus et al. World Allergy Organization Journal  (2018) 11:26 Page 11 of 11
